← back to search

Andrew D. Fesnak

Parker Institute for Cancer Immunotherapy · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include CAR-T cell therapy research, CRISPR and Genetic Engineering, Viral Infectious Diseases and Gene Expression in Insects, and Virus-based gene therapy research.
h-index
13
citations
3,305
works
53
NIH funding
—
primary concept
Medicine
email
fesnak@pennmedicine.upenn.edu

Recent publications

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Blood Cancer Discovery 2021cited by 288position: middledoi
CRISPR-engineered T cells in patients with refractory cancer
Science 2020cited by 1,428position: middledoi
Engineered T cells: the promise and challenges of cancer immunotherapy
Nature reviews. Cancer 2016cited by 1,055position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Mohamed Abou‐El‐Enein · University of Southern California1 papers (2021–2021)Gerhard Bauer · University of California, Davis1 papers (2021–2021)Peter Marks · UK Health Security Agency1 papers (2021–2021)Magdi Elsallab · Harvard University1 papers (2021–2021)Carl H. June · Weatherford College1 papers (2016–2016)Helen E. Heslop · Baylor College of Medicine1 papers (2021–2021)Bruce L. Levine · Cancer Research Center1 papers (2016–2016)Steven A. Feldman · Stanford University1 papers (2021–2021)Brian G. Till · University of Washington1 papers (2021–2021)Barbara Savoldo · University of North Carolina at Chapel Hill1 papers (2021–2021)